The Latest Cardiac and Vascular News
DUBLIN – August 9, 2018 – Medtronic plc (NYSE:MDT) today announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver lifesaving defibrillation and antitachycardia pacing therapy all in one system, […]
VANCOUVER, Aug. 8, 2018 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended June 30, […]
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented two-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago. The […]
BRUSSELS–(BUSINESS WIRE)–CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received European CE mark approval for its BRAVO Flow Diverter. The device is approved for use in the treatment of patients suffering from intracranial aneurysms. The device will divert blood flow from the aneurysm and […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone BioSciences, Inc., a biotechnology company focused on developing innovative drugs to treat neurotrauma and neurovascular disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The notice refers to a key patent application (US 15/590,815), which will […]
BLOOMINGTON, Ind.–(BUSINESS WIRE)–Cook Medical has introduced the 140 mm-length Zilver® PTX® Drug-Eluting Peripheral Stent in both 6 and 7 mm diameters in the U.S. The longer length comes after an expanded indication approval by FDA to treat total lesion lengths up to 300 mm per patient. In addition, the product […]
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Wedbush Pacgrow Healthcare Conference on Tuesday, August 14, 2018, at 10:55 a.m. […]
DUBLIN, Ohio, Aug. 7, 2018 /PRNewswire/ — N8 Medical, LLC (N8 Medical) today announced that the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) indicated its intent to fund N8 Medical’s STTR Phase I grant application for the development of a resorbable envelope to prevent surgical site […]
MONTREAL, Aug. 8, 2018 /PRNewswire/ — Milestone Pharmaceuticals, a clinical-stage cardiovascular company, today announced that the first patient has been randomized in its Phase 3 clinical study of etripamil. Etripamil is a new investigational, rapid-onset, short-acting calcium channel blocker administered intranasally by the patient designed to terminate paroxysmal supraventricular tachycardia (PSVT) episodes wherever […]
MARLBOROUGH, Mass., Aug. 8, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized the VICI VENOUS STENT® System for treating venous obstructive disease. Boston Scientific has been an investor in VENITI since 2016 and currently […]
